Association between intercellular adhesion molecule 1 (ICAM1) polymorphisms and diabetic foot susceptibility

Cao, Xue-Xia; Jy, Yang; Wang, Li

doi:10.1097/md.0000000000018052

Cited by 4 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intracellular Adhesion Molecule 1 ( ICAM1 ) encodes for a protein expressed on immune and endothelial cells. 28 It is thought to primarily mediate proinflammatory pathways through recruitment of immune cells and promotion of transendothelial migration of T lymphocytes into the dermis. 29,30 In addition to its association with psoriasis, ICAM1 has also been associated with vascular morphologic changes and cardiovascular disease, which strengthens the link between cardiovascular comorbidities and psoriasis.…”

Section: Resultsmentioning

confidence: 99%

Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline

Bui

Liu

Hong

et al. 2021

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

Background: Despite numerous genome-wide association studies conducted in psoriasis and psoriatic arthritis, only a small fraction of the identified genes has been therapeutically targeted. Objective: We sought to identify and analyze potential therapeutic targets for psoriasis and psoriatic arthritis (PsA) using the priority index (Pi), a genetics-dependent drug target prioritization approach. Methods: Significant genetic variants from GWAS for psoriasis, PsA, and combined psoriatic disease were annotated and run through the Pi pipeline. Potential drug targets were identified based on genomic predictors, annotation predictors, pathway enrichment, and pathway crosstalk. Results: Several gene targets were identified for psoriasis and PsA that demonstrated biological associations to their respective diseases. Some are currently being explored as potential therapeutic targets (i.e. ICAM1, NF-kB, REV3 L, ADRA1B for psoriasis; CCL11 for PsA); others have not yet been investigated (i.e. LNPEP, LCE3 for psoriasis; UBLCP1 for PsA). Additionally, many nodal points of potential intervention were identified as promising therapeutic targets. Of these, some are currently being studied such as TYK2 for psoriasis, and others have yet to be explored (i.e. PPP2CA, YAP1, PI3 K, AKT, FOXO1, RELA, CSF2, IFNGR1, IFNGR2 for psoriasis; GNAQ, PLCB1, GNAI2 for PsA). Conclusion: Through Pi, we identified data-driven candidate therapeutic gene targets and pathways for psoriasis and PsA. Given the sparse PsA specific genetic studies and PsA specific drug targets, this analysis could prove to be particularly valuable in the pipeline for novel psoriatic therapies.

show abstract

Section: Resultsmentioning

confidence: 99%

Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline

Bui

Liu

Hong

et al. 2021

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

show abstract

“…In a 2020 study[ 48 ] comprising 128 DF patients, 147 T2DM patients, and 155 healthy controls, Cao et al [ 48 ] examined the potential correlations between ICAM1 SNVs rs5498 and rs3093030, and susceptibility toward DF. The results revealed that the GG genotype of rs5498 was distinctly correlated with a decreased risk of developing both T2DM and DF, with the mutant allele G acting as a protective factor.…”

Section: Genetic Snvs Involved In Dfu Developmentmentioning

confidence: 99%

Single nucleotide variations in the development of diabetic foot ulcer: A narrative review

Hu¹,

Song²,

Jiang³

2022

World J Diabetes

View full text Add to dashboard Cite

Diabetes mellitus has become a global health problem, and the number of patients with diabetic foot ulcers (DFU) is rapidly increasing. Currently, DFU still poses great challenges to physicians, as the treatment is complex, with high risks of infection, recurrence, limb amputation, and even death. Therefore, a comprehensive understanding of DFU pathogenesis is of great importance. In this review, we summarized recent findings regarding the DFU development from the perspective of single-nucleotide variations (SNVs). Studies have shown that SNVs located in the genes encoding C-reactive protein, interleukin-6, tumor necrosis factor-alpha, stromal cell-derived factor-1, vascular endothelial growth factor, nuclear factor erythroid-2-related factor 2, sirtuin 1, intercellular adhesion molecule 1, monocyte chemoattractant protein-1, endothelial nitric oxide synthase, heat shock protein 70, hypoxia inducible factor 1 alpha, lysyl oxidase, intelectin 1, mitogen-activated protein kinase 14, toll-like receptors, osteoprotegerin, vitamin D receptor, and fibrinogen may be associated with the development of DFU. However, considering the limitations of the present investigations, future multi-center studies with larger sample sizes, as well as in-depth mechanistic research are warranted.

show abstract

“…Moderate patients often experienced dyspnea after 1 week. Some Severe patients progressed rapidly to Critical condition including multi-organ failure and even death (Huang et al 2020 ; Chen et al 2020 ; Cao et al 2020 ; Xu et al 2020a ).…”

Section: Introductionmentioning

confidence: 99%

New-onset COVID-19–related diabetes: an early indicator of multi-organ injury and mortally of SARS-CoV-2 infection

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objective The pandemic of 2019 coronavirus (SARS-CoV-2) disease (COVID-19) has imposed a severe public health burden worldwide. Most patients with COVID-19 were mild. Severe patients progressed rapidly to critical condition including acute respiratory distress syndrome (ARDS), multi-organ failure and even death. This study aims to find early multi-organ injury indicators and blood glucose for predicting mortality of COVID-19. Methods Fasting blood glucose (FBG) ≥7.0 mmol/L for two times during hospitalization and without a history of diabetes were defined as new-onset COVID-19-related diabetes (CRD). Indicators of injuries for multiple organs, including the lung, heart, kidney and liver, and glucose homeostasis were specifically analyzed for predicting death. Results A total of 120 patients with a severity equal to or greater than Moderate were hospitalized. After excluding patients with history of diabetes, chronic heart, kidney, and liver disease, 69 patients were included in the final analysis. Of the 69 patients, 23 were Moderate, 20 were Severe, and 26 were Critical (including 16 deceased patients). Univariable analysis indicated that CRD, lactate dehydrogenase (LDH), hydroxybutyrate dehydrogenase (HBDH), creatine kinase (CK) and creatinine (Cr) were associated with death. Multivariable analysis indicated that CRD was an independent predictor for death (HR = 3.75, 95% CI 1.26–11.15). Abnormal glucose homeostasis or CRD occurred earlier than other indicators for predicting poor outcomes. Indicators of multiple organ injury were in parallel with the expression patterns of ACE2 (the SARS-CoV-2 receptor) in different organs including pancreatic islet. Conclusions New-onset COVID-19-related diabetes is an early indicator of multi-organ injury and predictor for poor outcomes and death in COVID-19 patients. As it is easy to perform for clinical practices and self-monitoring, glucose testing will be helpful for predicting poor outcomes to facilitate appropriate intensive care.

show abstract

Association between intercellular adhesion molecule 1 (ICAM1) polymorphisms and diabetic foot susceptibility

Abstract: Supplemental Digital Content is available in the text

Cited by 4 publications

References 30 publications

Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline

Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline

Single nucleotide variations in the development of diabetic foot ulcer: A narrative review

New-onset COVID-19–related diabetes: an early indicator of multi-organ injury and mortally of SARS-CoV-2 infection

Contact Info

Product

Resources

About